News >

Gomella Gives Update on Nonmetastatic CRPC Advances

Angelica Welch
Published: Thursday, Oct 18, 2018

Dr. Leonard G. Gomella

Leonard G. Gomella, MD
The past year has brought therapeutic advancements to the nonmetastatic (M0) castration-resistant prostate cancer (CRPC) paradigm, but more is on the horizon for these patients, according to Leonard G. Gomella, MD.

In February 2018, the FDA approved the first therapy for patients in this setting. Apalutamide (Erleada) was approved for the treatment of patients with M0 CRPC based on findings from the phase III SPARTAN trial, in which the agent plus androgen deprivation therapy (ADT) reduced the risk of metastasis or death by 72%.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication